References
Original article
Benjamin, R. et al. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol. https://doi.org/10.1016/S2352-3026(22)00245-9 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sidaway, P. Allogeneic CAR T cells show promise. Nat Rev Clin Oncol 19, 748 (2022). https://doi.org/10.1038/s41571-022-00703-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-022-00703-4
- Springer Nature Limited